187 related articles for article (PubMed ID: 35786627)
21. Update on Metastatic Uveal Melanoma: Progress and Challenges.
Spagnolo F; Picasso V; Spano L; Tanda E; Venzano C; Queirolo P
BioDrugs; 2016 Jun; 30(3):161-72. PubMed ID: 27000042
[TBL] [Abstract][Full Text] [Related]
22. The "ART" of Epigenetics in Melanoma: From histone "Alterations, to Resistance and Therapies".
Strub T; Ballotti R; Bertolotto C
Theranostics; 2020; 10(4):1777-1797. PubMed ID: 32042336
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic signaling in uveal melanoma.
Park JJ; Diefenbach RJ; Joshua AM; Kefford RF; Carlino MS; Rizos H
Pigment Cell Melanoma Res; 2018 Nov; 31(6):661-672. PubMed ID: 29738114
[TBL] [Abstract][Full Text] [Related]
24. Metastatic disease from uveal melanoma: treatment options and future prospects.
Carvajal RD; Schwartz GK; Tezel T; Marr B; Francis JH; Nathan PD
Br J Ophthalmol; 2017 Jan; 101(1):38-44. PubMed ID: 27574175
[TBL] [Abstract][Full Text] [Related]
25. Uveal melanoma: Towards a molecular understanding.
Smit KN; Jager MJ; de Klein A; Kiliҫ E
Prog Retin Eye Res; 2020 Mar; 75():100800. PubMed ID: 31563544
[TBL] [Abstract][Full Text] [Related]
26. The genetics of uveal melanoma: an emerging framework for targeted therapy.
Harbour JW
Pigment Cell Melanoma Res; 2012 Mar; 25(2):171-81. PubMed ID: 22268848
[TBL] [Abstract][Full Text] [Related]
27. Genetic study of familial uveal melanoma: association of uveal and cutaneous melanoma with cutaneous and ocular nevi.
Smith JH; Padnick-Silver L; Newlin A; Rhodes K; Rubinstein WS
Ophthalmology; 2007 Apr; 114(4):774-9. PubMed ID: 17207529
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic implications of the emerging molecular biology of uveal melanoma.
Patel M; Smyth E; Chapman PB; Wolchok JD; Schwartz GK; Abramson DH; Carvajal RD
Clin Cancer Res; 2011 Apr; 17(8):2087-100. PubMed ID: 21444680
[TBL] [Abstract][Full Text] [Related]
29. Current molecular and clinical insights into uveal melanoma (Review).
Fallico M; Raciti G; Longo A; Reibaldi M; Bonfiglio V; Russo A; Caltabiano R; Gattuso G; Falzone L; Avitabile T
Int J Oncol; 2021 Apr; 58(4):. PubMed ID: 33649778
[TBL] [Abstract][Full Text] [Related]
30. The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas.
Makohon-Moore AP; Lipson EJ; Hooper JE; Zucker A; Hong J; Bielski CM; Hayashi A; Tokheim C; Baez P; Kappagantula R; Kohutek Z; Makarov V; Riaz N; Postow MA; Chapman PB; Karchin R; Socci ND; Solit DB; Chan TA; Taylor BS; Topalian SL; Iacobuzio-Donahue CA
Clin Cancer Res; 2021 Mar; 27(5):1516-1525. PubMed ID: 33323400
[TBL] [Abstract][Full Text] [Related]
31. Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.
Chua V; Lapadula D; Randolph C; Benovic JL; Wedegaertner PB; Aplin AE
Mol Cancer Res; 2017 May; 15(5):501-506. PubMed ID: 28223438
[TBL] [Abstract][Full Text] [Related]
32. Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
[TBL] [Abstract][Full Text] [Related]
33. Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling.
Griewank KG; Koelsche C; van de Nes JAP; Schrimpf D; Gessi M; Möller I; Sucker A; Scolyer RA; Buckland ME; Murali R; Pietsch T; von Deimling A; Schadendorf D
Clin Cancer Res; 2018 Sep; 24(18):4494-4504. PubMed ID: 29891723
[No Abstract] [Full Text] [Related]
34. Research in practice: Therapeutic targeting of oncogenic GNAQ mutations in uveal melanoma.
Gaffal E
J Dtsch Dermatol Ges; 2020 Nov; 18(11):1245-1248. PubMed ID: 32954611
[TBL] [Abstract][Full Text] [Related]
35. Integrin expression in uveal melanoma differs from cutaneous melanoma.
ten Berge PJ; Danen EH; van Muijen GN; Jager MJ; Ruiter DJ
Invest Ophthalmol Vis Sci; 1993 Dec; 34(13):3635-40. PubMed ID: 8258522
[TBL] [Abstract][Full Text] [Related]
36. Metabolic Alterations and Therapeutic Opportunities in Rare Forms of Melanoma.
Han A; Schug ZT; Aplin AE
Trends Cancer; 2021 Aug; 7(8):671-681. PubMed ID: 34127435
[TBL] [Abstract][Full Text] [Related]
37. Infrequent expression of the MAGE gene family in uveal melanomas.
Mulcahy KA; Rimoldi D; Brasseur F; Rodgers S; Liénard D; Marchand M; Rennie IG; Murray AK; McIntyre CA; Platts KE; Leyvraz S; Boon T; Rees RC
Int J Cancer; 1996 Jun; 66(6):738-42. PubMed ID: 8647642
[TBL] [Abstract][Full Text] [Related]
38. Pathology and genetics of uveal melanoma.
Griewank KG; Murali R
Pathology; 2013 Jan; 45(1):18-27. PubMed ID: 23222249
[TBL] [Abstract][Full Text] [Related]
39. Major cytogenetic aberrations and typical multidrug resistance phenotype of uveal melanoma: current views and new therapeutic prospects.
Baggetto LG; Gambrelle J; Dayan G; Labialle S; Barakat S; Michaud M; Grange JD; Gayet L
Cancer Treat Rev; 2005 Aug; 31(5):361-79. PubMed ID: 15994016
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma.
Slater K; Hoo PS; Buckley AM; Piulats JM; Villanueva A; Portela A; Kennedy BN
Cancer Metastasis Rev; 2018 Sep; 37(2-3):335-345. PubMed ID: 30094568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
